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Objective: To better understand sexual dysfunction in patients with schizophrenia and its 
associations with prolactin and reproductive hormones.
Methods: This was a secondary analysis of an open-label, one-day study (N = 402). The 
primary objective of the study was to assess the prevalence of hyperprolactinemia in patients 
with schizophrenia who had been treated with conventional antipsychotics or risperidone. 
Other atypical antipsychotics available at the time of the study were not included due to a more 
favorable prolactin proﬁ  le.
Results: The majority of patients (59% of females and 60% of males) reported impairment 
of sexual function. In postmenopausal females, risk of impaired sexual interest was increased 
by 31% for every 10 ng/ml increase in prolactin (p = 0.035). In males, lower testosterone was 
associated with higher prolactin (p  0.001) and with orgasmic (p = 0.004) and ejaculatory 
dysfunction (p = 0.028).
Conclusion: These ﬁ  ndings suggest that hyperprolactinemia may be associated with sexual 
dysfunction. They also provide more information on the relationships between prolactin, 
reproductive hormones, and sexual dysfunction. Sexual dysfunction is an understudied yet 
important consideration in the treatment of schizophrenia. More attention is warranted in this 
area as it may provide opportunities for improved quality of life and adherence to treatment 
for patients.
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Introduction
Sexual dysfunction is commonly experienced by patients with schizophrenia receiving 
antipsychotic drug treatment and has been reported to occur more frequently with 
conventional antipsychotics.1–5 Treatment-emergent sexual dysfunction in this 
patient population includes impairment of libido, orgasmic function, and erectile and 
ejaculatory function.1,6,7 While this syndrome has not been extensively researched 
in large, controlled studies, treatment-emergent sexual dysfunction is known to 
result in physical and psychological distress and can negatively inﬂ  uence treatment 
compliance.6–9
The relatively high prevalence of sexual dysfunction in patients treated with anti-
psychotics has been associated with elevations in prolactin, an effect attributed to the 
acute and chronic dopamine-blocking effect of this drug class.12–15 The mechanism by 
which prolactin elevation inﬂ  uences sexual dysfunction is unclear. Published reports 
have suggested that elevations in prolactin adversely affect sexual function indirectly 
via downregulation of estradiol16 or testosterone,17,18 although others have reported 
correlations between hyperprolactinemia and sexual dysfunction independent of those 
hormone levels.19–22Neuropsychiatric Disease and Treatment 2009:5 48
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The development of acute movement disorders such 
as tardive dyskinesia and extrapyramidal symptoms has 
also been reported during treatment with antipsychotic 
medications.23,24 These abnormalities have been reported 
to occur with a higher prevalence during treatment with 
conventional antipsychotics than with atypical antipsychotics, 
and their adverse impact on quality of life and treatment 
compliance has been documented.24–31
In addition to treatment-related factors that may be 
associated with sexual dysfunction, behavioral factors such 
as use of caffeine, alcohol, and tobacco also are worthy of 
investigation. Cigarette smoking is known to occur with 
greater prevalence among patients with schizophrenia than 
among the adult population overall, and published reports 
indicate that this population consumes more caffeine daily32,33 
and has a higher prevalence of alcohol dependency.34
The objective of this research is to better understand 
the relationships between sexual dysfunction, prolactin, 
and reproductive hormones. Potential associations between 
sexual functioning and acute movement disorders as well as 
behavioral factors including caffeine, alcohol, and tobacco 
were also explored. These variables are of interest because all 
may be attributable to some degree to a dopamine D2 receptor 
blockade. High levels of D2 occupancy have been associated 
with hyperprolactinemia, extrapyramidal symptoms, as well 
as worsening of mood and depressive symptoms.35–44
Methods
This was a secondary analysis of a one-day, multicenter, 
observational study. The primary objective of the study as 
well as a brief description of the study is provided below. 
Additional details can be found in the primary report of the 
study.16
Subjects
This study included patients meeting American Psychiatric 
Association (APA) criteria for schizophrenia, schizoaffec-
tive disorder, or schizophreniform disorder (Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition 
[DSM-IV; APA, 1994]). Patients must be between 18 and 
70 years of age and have received treatment with a conven-
tional antipsychotic drug or risperidone for at least three 
months prior to entering the study. Medications were pre-
scribed by the patients’ psychiatrists using clinical judgment. 
Conventional antipsychotics and risperidone were included 
in the study due to their associations with elevated prolactin. 
Patients taking antipsychotic drugs with a more favorable 
prolactin proﬁ  le (clozapine, olanzapine, and quetiapine) 
or concomitant prolactin-elevating medications were not 
included. At the time the study protocol was designed and 
approved (1998), there were no other atypical antipsychotics 
available. Other key exclusion criteria for the study included 
pregnancy, nursing, sex hormone therapy, DSM-IV substance 
abuse or dependency, and thyroid or pituitary gland diseases. 
Patients who met the above selection criteria during the 
screening were scheduled to enter the one-day clinical visit 
after their informed consent documents have been received. 
Each study site’s Institutional Review Board approved the 
informed consent documents as well as the study protocol, 
which was developed in accordance with the ethical standards 
of good clinical practice and the Declaration of Helsinki.
Study design
This study was conducted at 27 centers in the United States 
from September 1998 through May 2000. Patients were 
requested to have abstained from sexual activity within 
12 hours prior to the visit. Patients arrived at the study center 
in the morning, and blood was collected for measurement 
of serum prolactin, estradiol in females, and total and free 
testosterone in males. Patients were given a small bland 
meal, and a second blood sample was collected three to four 
hours later from which a second prolactin measurement was 
obtained. Each patient’s prolactin level was considered as 
the mean value from the two blood samples.
Assay methodology
Whole blood samples were centrifuged to separate serum. Serum 
was shipped at ambient temperature on the day of collection 
and assayed by Covance Central Laboratory (Indianapolis, IN). 
Prolactin was assayed by microparticle enzyme immunoassay 
(sensitivity 0.60 ng/mL, intra-assay coefﬁ  cients of variation 
[c.v.] 3.2%–3.6%, inter-assay c.v. 4.5%–5.2%). Testosterone 
was measured using Coat-a-Count radioimmunoassay procedure 
(assay sensitivity 8.0 ng/dL, intra-assay c.v. 11.2%, inter-assay 
c.v. 11.0%). Estradiol was measured using a double-antibody 
radioassay procedure (sensitivity 1.4 pg/mL, intra-assay c.v. 
6.5%, inter-assay c.v. 7.6%).
Assessment of sexual dysfunction
The Global Impression of Sexual Function (GISF) is a 
self-rated scale by patient that measures a subject’s feelings 
toward his or her sexual function. The GISF is designed to 
assess sexual interest/desire, arousal (as characterized by 
penile erection or vaginal lubrication), orgasm, and overall 
sexual function. Each item was rated from 1 (“normal”) to 
5 (“severely impaired”).Neuropsychiatric Disease and Treatment 2009:5 49
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The Changes in Sexual Functioning Questionnaire 
(CSFQ) is a clinician-rated, structured interview/question-
naire designed to measure dysfunction and changes in sexual 
function during treatment with medication.45 The CSFQ, 
which consists of 36 questions for men and 35 questions 
for women, assesses components of sexuality pertaining 
to pleasure, desire/frequency, desire/interest, arousal, and 
orgasm.
Assessment of extrapyramidal symptoms
The Simpson–Angus Scale46 is an assessment tool used to 
measure treatment-emergent parkinsonism. The modiﬁ  ed 
version of the scale used in this study eliminated items 
relating to head drop and leg pendulousness; combined items 
pertaining to shoulder shaking, elbow rigidity, and ﬁ  xation 
of position; and added items on balance, akinesia, akathisia, 
acute dystonic reaction, and cooperativeness.
The Barnes Akathisia Scale47 was used to assess observ-
able movements of treatment-emergent akathisia, subjective 
awareness and distress associated with akathisia, and provide 
a global clinical assessment of severity.
The Abnormal Involuntary Movement Scale (AIMS)48 
was used to record the occurrence of dyskinetic move-
ments in speciﬁ  c body regions and assess the severity, 
level of incapacitation, and subject’s awareness of the 
movements.
Assessment of caffeine/alcohol/tobacco use
Patients’ past and current use of caffeine, alcohol, and 
tobacco was obtained from medical histories and subjects’ 
self-reports. Specifically, the current use was assessed 
through questions with regard to the weekly consumption 
of alcohol including beer, spirits, and wine; total daily use 
of tobacco; number of years smoked; and average daily 
consumption of caffeine.
Statistical methods
Patient characteristics were tabulated by gender. Fisher’s 
exact test was used to compare male and female patients’ 
social and reproductive histories and responses to sexual 
functioning questionnaires. Fisher’s exact test was also 
used to compare hyperprolactemia status among females. 
Hyperprolactinemia was deﬁ  ned as a prolactin level above 
the upper limit of normal (0.8 nmol/L [18.77 ng/mL] for 
males and 1.05 nmol/L [24.20 ng/mL] for females). Different 
aspects of sexual dysfunction were deﬁ  ned using a criterion 
of a score 3 on each of the four GISF items and analyzed 
separately for males and females.
The effect of prolactin level on different aspects of sexual 
dysfunction was modeled using a logistic regression model 
with prolactin level as the independent variable. The effects 
of estradiol (for females) and free and total testosterone (for 
males) on sexual functioning based on both GISF and CSFQ 
were also analyzed with a logistic regression model after 
adjusting for age. In addition, logistic regression analyses 
were conducted to assess the dose response relationship 
associated with sexual dysfunction. The association of 
prolactin level and sex hormones were tested using a Pearson 
correlation test.
Linear regression was used to examine the relationship 
between sexual dysfunction and acute movement disorders 
after adjusting for age. Each item of the Simpson–Angus 
Scale, Barnes Akathisia Scale, and AIMS were used as 
individual predictors. The association of prolactin level 
and acute movement disorders was tested using Spearman’s 
rank correlation test. Multiple linear regression was used 
to test the relationship between sexual dysfunction and 
behavioral habits. The number of caffeinated drinks 
(daily), cigarettes (cigars, pipes: daily), or alcoholic drinks 
(weekly) were used as individual predictors after adjust-
ing for age.
As the analyses in this research were secondary and 
exploratory in nature, no corrections for multiple compari-
sons were made.
Results
Demographics and disease characteristics
Patient demographics and disease characteristics are 
summarized by gender in Table 1. Use of specific 
antipsychotic drugs and their doses are also presented 
in the table. The majority of subjects were Caucasian. 
Mean age was 40.8 (±10.0) for males and 44.5 (±11.4) 
for females. Approximately one-third of subjects were 
receiving risperidone, and two-thirds were receiving con-
ventional antipsychotics. Of the female subjects, 61% were 
premenopausal, 35% were postmenopausal, and 4% were 
perimenopausal or of unknown status. Hyperprolactinemia 
was present in 42% of males and 59% of females, including 
66% of premenopausal females and 45% of postmeno-
pausal females.
Patients’ social and reproductive history is summarized 
by gender. Relatively few subjects (8% of males and 19% 
of females) described themselves as married or cohabitating. 
Education history and current employment were similar for 
male and female patients. Approximately one-quarter of 
patients were high school graduates but fewer than 10% were Neuropsychiatric Disease and Treatment 2009:5 50
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college graduates, and more than 80% were unemployed 
at the time of the study. Fewer male patients than female 
patients reported biologic offspring (33% compared with 
57%, p  0.001).
Prevalence of sexual dysfunction
Majority of patients (59% of females and 60% of males) 
reported impairment of overall sexual function. The preva-
lence rate of overall sexual dysfunction did not differ based 
on type of drug treatment (risperidone vs conventional 
antipsychotics), regardless of whether the population was 
analyzed overall or by gender.
Association between age and sexual 
dysfunction
The relationship between age and sexual dysfunction was 
signiﬁ  cant for male patients (odds ratio [OR] = 1.04; 95% 
conﬁ  dence interval [CI] [1.01–1.07], p = 0.003), indicating 
that the odds of sexual dysfunction was increased by 40% with 
each 10-year age increase in males. The correlation between 
Table 1 Patient and disease characteristics
Males (n = 255) Females (n = 147)
Age (mean ± SD) 40.8 ± 10.0 44.5 ± 11.4
Race (n/%)
  Caucasian 124 (48.6%) 62 (42.2%)
  African descent 96 (37.6%) 68 (46.2%)
  Asian descent 7 (2.7%) 6 (4.1%)
  Other 28 (11.0%) 11 (7.5%)
Menopausal Status (n/%)
 Premenopausal 90 (61.2%)
 Postmenopausal 51 (34.7%)
 Perimenopausal/unknown 6 (4.0%)
Serum prolactina
  Below upper limit of normalb 147 (57.6%) 60 (40.8%)
  Elevated 108 (42.4%) 87 (59.2%)
Diagnosis
 Schizophrenia 85.5% 76.2%
 Schizoaffective 14.5% 23.8%
  Length of illness (yrs ± SD) 17.2 ± 9.7 18.7 ± 11.3
Drug n/mean dose (mg/day)
 Risperidone 84/5.2 42/4.7
  Conventional – Oral
   Chlorpromazine 7/157.14 3/266.67
   Fluphenazine 11/21.32 12/13.06
   Haloperidol 28/14.32 16/8.69
   Loxapine 4/86.25 3/41.67
   Mesoridazine 3/166.67 2/27.50
   Molindone 1/125.00 0
   Perphenazine 5/8.40 9/14.44
   Pimozide 1/4.00 0
   Thioridazine  hydrochloride 14/294.64 11/295.45
   Tiotixene 10/21.50 5/8.00
   T r i ﬂ  uoperazine 3/23.33 5/14.40
  Conventional – depot (mg/month)
   Fluphenazine  decanoate 43/74.4 18/60.94
   Haloperidol  decanoate 41/138.5 20/133.45
Notes: aOnly patients whose serum prolactin and reproductive hormone values were available are included; bThe upper limit of normal (ULN) for serum prolactin was deﬁ  ned 
as 18.77 ng/mL for males and 24.20 ng/mL for females.Neuropsychiatric Disease and Treatment 2009:5 51
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age and sexual dysfunction did not reach statistical signiﬁ  cance 
for females (OR = 1.02; CI [0.96, 1.05], p = 0.29).
Association between dose and sexual 
dysfunction
A signiﬁ  cant dose response was observed in males on ris-
peridone treatment (Figure 1), among whom the odds of 
impaired orgasm was increased by 26% (OR = 1.26%; 95% CI 
[1.03–1.54]; p = 0.02) for every 1 mg increase in risperidone. 
Otherwise, signiﬁ  cant relationships between drug dose and 
any aspect of sexual functioning (sexual interest/desire, 
vaginal lubrication/erection, or overall) were not observed in 
any group of patients (males, premenopausal females, or post-
menopausal females) regardless of type of drug treatment.
Association between elevated prolactin 
and sexual dysfunction
An increase in prolactin level in female patients was 
associated with greater odds of impaired sexual interest 
(OR = 1.009; 95% CI [1.000–1.019]; p = 0.052). This effect 
was driven primarily by postmenopausal females, among 
whom the odds of impaired sexual interest are increased by 
31% (OR = 1.031; 95% CI [1.002–1.060]; p = 0.035) for 
every 10 ng/mL increase in prolactin.
Elevated prolactin was not associated with sexual 
dysfunction among males in the overall population or among 
males treated with conventional antipsychotics. However, an 
association between elevated prolactin and impairment of 
orgasm was observed among males treated with risperidone 
(OR = 1.031; 95% CI [1.002–1.062]; p = 0.039).
Role of estradiol and testosterone 
in sexual dysfunction
When adjusted for age, estradiol level did not have a 
signiﬁ  cant effect on any aspect of sexual functioning in 
female patients. Among male patients, both total and free 
testosterone were negatively correlated with prolactin level 
(correlation coefﬁ  cient = –0.22 and –0.28, p = 0.0003 and 
p = 0.0001, respectively). When adjusted for age, lower 
concentration of total testosterone was associated with an 
inability to ejaculate when desired (p = 0.028), and lower 
concentration of free testosterone was associated with painful 
orgasm (p = 0.004; Table 2) based on CSFQ measures.
Association between acute movement 
disorders and sexual dysfunction
In male patients after adjusting for age, impairment of sexual 
function was associated with involuntary movement of the lower 
body, impaired balance, excessive salivation, akinesia, and 
akathisia. Age was associated with worse outcomes on multiple 
measures of the acute movement scales. Due to the size, data are 































































Male subjects Impaired orgasm
Figure 1 Prevalence of impaired orgasm by risperidone dose in male subjects (n = 87). Impairment of orgasm was deﬁ  ned as a score 3 on the orgasm component of the 
Global Impressions of Sexual Function questionnaire.Neuropsychiatric Disease and Treatment 2009:5 52
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In female patients after adjusting for age, impairment of 
sexual function was associated with involuntary movement 
of facial expression muscles and impaired balance. Age was 
associated with a worse outcome on a single component of 
the modiﬁ  ed Simpson–Angus scale. Due to the size, data are 
not presented here and will be available upon request.
An examination of the possible association between prolac-
tin level and acute movement disorders revealed the associa-
tions between prolactin and the three movement scales were 
not statistically signiﬁ  cant for both males and females.
Association between caffeine/alcohol/
tobacco use and sexual dysfunction
In male patients after adjusting for age, daily smoking (daily 
number of cigarettes and/or total daily smoking) and years 
smoked were both associated with better scores in erections, 
orgasm, and overall sexual function, and greater number of 
years smoked was associated with a higher degree of sexual 
interest/desire. Sexual dysfunction was not associated with 
alcohol or caffeine use in either males or females.
Discussion
Data presented in this paper revealed a sexual dysfunction prev-
alence rate of approximately 60%, regardless of gender, which 
was consistent with published reports.1,7,9 Elevated prolactin 
levels were found to be associated with sexual dysfunction.
Some reports have suggested that sexual dysfunction 
ultimately results from prolactin-mediated down-regulation 
of serum testosterone or estradiol.16–18 Data in this research 
indicate that prolactin elevations in males were correlated 
with lower levels of total and free serum testosterone. Those 
reductions, in turn, were associated with dysfunction relating 
to orgasm and ejaculation. This suggests that the association 
between hyperprolactinemia and sexual dysfunction in males 
may be mediated by reductions in testosterone.
Prolactin elevations also were associated with impaired 
sexual interest in postmenopausal women. The associations 
between prolactin and estradiol, and between estradiol and 
sexual dysfunction, were not signiﬁ  cant.
Few reports have addressed the possible association 
between acute movement disorders associated with anti-
psychotic treatment and sexual dysfunction in patients with 
schizophrenia. Our data indicate an association between 
various components of sexual dysfunction and movement 
disorders relating to tardive dyskinesia, parkinsonism, and 
akathisia. The underlying mechanism of this potential asso-
ciation is not well understood. As prolactin was not associated 
with movement disorders, it is not likely a mediator for the 
relationship between movement and sexual functions. Further 
studies are needed to conﬁ  rm the association seen between 
movement disorders and sexual dysfunction and to explore 
the potential underlying mechanism.
One unexpected outcome in this research was that tobacco 
smoking was signiﬁ  cantly correlated with better sexual 
functioning in males. This ﬁ  nding was somewhat surprising, 
given that smoking has been associated with male erectile 
dysfunction.49 However, tobacco smoking has been linked 
to enhancing the metabolism and excretion of antipsychotic 
agents.50,51 Thus, it may be possible that the association 
between tobacco smoking and better sexual functioning in 
males was attributable to faster clearance of the antipsychotic 
agents in those patients. Future studies are needed to further 
explore this potential theory.
An important limitation that needs discussion is that the 
study did not include other atypical antipsychotic drugs than 
risperidone. As the primary objective of the study was to 
evaluate prevalence of hyperprolactinemia, only conventional 
antipsychotics and risperidone were included in the study due 
to their associations with elevated prolactin levels. Atypical 
antipsychotic drugs with a more favorable prolactin proﬁ  le 
(clozapine, olanzapine, and quetiapine) were not included. 
There were no other atypical antipsychotics available at the time 
the study protocol was designed and approved (1998). Prospec-
tive and controlled future studies to facilitate the comparison 
Table 2 Age-adjusted association between serum testosterone and sexual dysfunction in male subjects
CSFQ Item Prevalence 
of dysfunction
Total testosterone Free testosterone
p valuea Odds ratio 95% CI p valuea Odds ratio 95% CI
Ejaculate when wanted 20.2% 0.028 0.998 0.996, 1.000 0.102 0.954 0.902, 1.009
Painful orgasm 6.3% 0.455 1.001 0.998, 1.004 0.004 1.175 1.052, 1.312
Abbreviations: CI, conﬁ  dence interval; CSFQ, Changes in Sexual Functioning Questionnaire.
Notes: aP values were obtained by logistic regression.   As measured by CSFQ, sexual dysfunction was deﬁ  ned as a score of 1 or 2 for “ejaculate when wanted”, and a score 
of 3 or greater for “painful orgasm.”Neuropsychiatric Disease and Treatment 2009:5 53
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of risperidone and conventionals to antipsychotics with a more 
favorable prolactin proﬁ  le are needed and will help to better 
ascertain the effect of prolactin on sexual functioning.
A second limitation of the present research is that CSFQ 
has not been speciﬁ  cally validated in schizophrenia patients 
treated with antipsychotics. The Psychotropic-Related Sexual 
Dysfunction (PRSexDQ-SALSEX) is a brief and relatively 
nonintrusive questionnaire and has been recently validated 
in a sample of patients with schizophrenia or other psychotic 
disorders who were experiencing anti-psychotic-induced 
sexual dysfunction and were switched to olanzapine.52
Another limitation is that the study was designed to be 
a one-day clinic visit, thus, only allowing a cross-sectional 
examination of prolactin level and its association with sexual 
dysfunction. Prospective studies that follow patients over a 
period of time will be able to provide further information on 
the time course of the development of sexual dysfunction and 
the effect of prolactin on sexual dysfunction over time.
Overall, these data suggest that elevated prolactin was 
associated with sexual dysfunction. They also provide more 
information on the relationships between prolactin, repro-
ductive hormones, and sexual functioning in patients with 
schizophrenia. Sexual dysfunction is an understudied yet 
important consideration in the treatment of schizophrenia. 
More attention is warranted in this area as it may provide 
opportunities for improved quality of life and adherence to 
treatment for patients.6–9
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